Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Alexandr S. Zhuravlev"'
Autor:
Tatyana N. Sokolova, Fedor V. Moiseyenko, Alexey A Kudriavtsev, Aglaya G. Iyevleva, Natalia V. Mitiushkina, Mikhail M Kramchaninov, Alexandr O. Ivantsov, Svetlana N. Aleksakhina, Grigoriy A. Yanus, Nikita M. Volkov, Elena V. Preobrazhenskaya, Kseniya S. Kozyreva, Kseniya V. Shelekhova, Ilya V. Bizin, Alexandr S. Zhuravlev, Ekatherina Sh. Kuligina, Aigul R. Venina, Evgeny N. Imyanitov, Denis V Pashkov, Anna P. Sokolenko, Vyacheslav A. Chubenko, Vladimir M. Moiseyenko, Alexandr V. Togo
Publikováno v:
Clinical Drug Investigation. 38:553-562
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF). Most clinical trials for chemo-naive CRC p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e2e1149754d9023df32db8536d94f2
https://doi.org/10.1007/s40261-018-0629-1
https://doi.org/10.1007/s40261-018-0629-1
Autor:
Nikita M. Volkov, Kseniya V. Shelekhova, Alexandr O. Ivantsov, Elena V. Preobrazhenskaya, Michail M. Kramchaninov, Fedor V. Moiseyenko, Kseniya S. Kozyreva, Svetlana N. Aleksakhina, Aigul R. Venina, Natalia V. Mitiushkina, Aglaya G. Iyevleva, Vyacheslav A. Chubenko, Alexandr S. Zhuravlev, Evgeny N. Imyanitov, Vladimir M. Moiseyenko
Publikováno v:
Oncology Research and Treatment. 39:605-614
Background: Discontinuation of gefitinib treatment is often accompanied by a disease flare. Some studies have demonstrated a benefit of the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) beyond progression; however, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd528fca4a6493411b4a83ae51ef526
https://doi.org/10.1159/000449024
https://doi.org/10.1159/000449024